100 related articles for article (PubMed ID: 34260066)
1. SARS-CoV-2 reinfection in a cancer patient with a defective neutralizing humoral response.
Borgogna C; De Andrea M; Griffante G; Lai A; Bergna A; Galli M; Zehender G; Castello L; Ravanini P; Cattrini C; Mennitto A; Gennari A; Gariglio M
J Med Virol; 2021 Dec; 93(12):6444-6446. PubMed ID: 34260066
[No Abstract] [Full Text] [Related]
2. Symptomatic reinfection of SARS-CoV-2 with spike protein variant N440K associated with immune escape.
Rani PR; Imran M; Lakshmi JV; Jolly B; Jain A; Surekha A; Senthivel V; Chandrasekhar P; Divakar MK; Srinivasulu D; Bhoyar RC; Vanaja PR; Scaria V; Sivasubbu S
J Med Virol; 2021 Jul; 93(7):4163-4165. PubMed ID: 33818797
[No Abstract] [Full Text] [Related]
3. Protective immunity after recovery from SARS-CoV-2 infection.
Kojima N; Klausner JD
Lancet Infect Dis; 2022 Jan; 22(1):12-14. PubMed ID: 34762853
[No Abstract] [Full Text] [Related]
4. Protection against reinfection with D614- or G614-SARS-CoV-2 isolates in golden Syrian hamster.
Brustolin M; Rodon J; Rodríguez de la Concepción ML; Ávila-Nieto C; Cantero G; Pérez M; Te N; Noguera-Julián M; Guallar V; Valencia A; Roca N; Izquierdo-Useros N; Blanco J; Clotet B; Bensaid A; Carrillo J; Vergara-Alert J; Segalés J
Emerg Microbes Infect; 2021 Dec; 10(1):797-809. PubMed ID: 33825619
[TBL] [Abstract][Full Text] [Related]
5. Recovery scenario and immunity in COVID-19 disease: A new strategy to predict the potential of reinfection.
Khoshkam Z; Aftabi Y; Stenvinkel P; Paige Lawrence B; Rezaei MH; Ichihara G; Fereidouni S
J Adv Res; 2021 Jul; 31():49-60. PubMed ID: 33520309
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Reinfection in a Healthcare Worker Despite the Presence of Detectable Neutralizing Antibodies.
Brehm TT; Pfefferle S; von Possel R; Kobbe R; Nörz D; Schmiedel S; Grundhoff A; Olearo F; Emmerich P; Robitaille A; Günther T; Braun P; Andersen G; Knobloch JK; Addo MM; Lohse AW; Aepfelbacher M; Fischer N; Schulze Zur Wiesch J; Lütgehetmann M
Viruses; 2021 Apr; 13(4):. PubMed ID: 33921216
[TBL] [Abstract][Full Text] [Related]
7. Viral Shedding among Re-Positive Severe Acute Respiratory Syndrome Coronavirus-2 Positive Individuals in Republic of Korea.
Kim JM; Ryu B; Choe YJ; Jo HJ; Lee H; Kim HM; Lee NJ; Rhee JE; Chung YS; Han MG; Kim EJ; Park Y; Gwack J; Jin Y; Song J; Seo S; Gill B; Kim H; Park Y; Yoo CK; Jeong EK
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696519
[TBL] [Abstract][Full Text] [Related]
8. Evolution of antibody responses up to 13 months after SARS-CoV-2 infection and risk of reinfection.
Gallais F; Gantner P; Bruel T; Velay A; Planas D; Wendling MJ; Bayer S; Solis M; Laugel E; Reix N; Schneider A; Glady L; Panaget B; Collongues N; Partisani M; Lessinger JM; Fontanet A; Rey D; Hansmann Y; Kling-Pillitteri L; Schwartz O; De Sèze J; Meyer N; Gonzalez M; Schmidt-Mutter C; Fafi-Kremer S
EBioMedicine; 2021 Sep; 71():103561. PubMed ID: 34455390
[TBL] [Abstract][Full Text] [Related]
9. Critical role of neutralizing antibody for SARS-CoV-2 reinfection and transmission.
Kim YI; Kim SM; Park SJ; Kim EH; Yu KM; Chang JH; Kim EJ; Casel MAB; Rollon R; Jang SG; Um J; Song MS; Jeong HW; Kim EG; Kim Y; Kim SY; Park JS; Park MS; Kwon GY; Yeo SG; Lee SA; Choi YJ; Jung JU; Choi YK
Emerg Microbes Infect; 2021 Dec; 10(1):152-160. PubMed ID: 33407005
[TBL] [Abstract][Full Text] [Related]
10. Correlates of protection from SARS-CoV-2 infection.
Krammer F
Lancet; 2021 Apr; 397(10283):1421-1423. PubMed ID: 33844964
[No Abstract] [Full Text] [Related]
11. Robust Neutralizing Antibody Levels Detected after Either SARS-CoV-2 Vaccination or One Year after Infection.
Glöckner S; Hornung F; Baier M; Weis S; Pletz MW; Deinhardt-Emmer S; Löffler B; The CoNAN Study Group
Viruses; 2021 Oct; 13(10):. PubMed ID: 34696428
[TBL] [Abstract][Full Text] [Related]
12. Relationship between Antibody Levels and SARS-Cov-2 Reinfection.
Islamoglu MS; Cengiz M; Uysal BB; Ikitimur H; Ozdemir Z; Karamehmetoglu A; Akbulut AE; Bakdur AN; Ozdemir A; Kayıkcıoglu H; Ozdemir H; Uces R; Ersoy S; Yavuzer S
Ann Clin Lab Sci; 2021 Nov; 51(6):750-755. PubMed ID: 34921027
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal Immune Profiling of a Severe Acute Respiratory Syndrome Coronavirus 2 Reinfection in a Solid Organ Transplant Recipient.
Klein J; Brito AF; Trubin P; Lu P; Wong P; Alpert T; Peña-Hernández MA; Haynes W; Kamath K; Liu F; Vogels CBF; Fauver JR; Lucas C; Oh J; Mao T; Silva J; Wyllie AL; Muenker MC; Casanovas-Massana A; Moore AJ; Petrone ME; Kalinich CC; Dela Cruz C; Farhadian S; Ring A; Shon J; Ko AI; Grubaugh ND; Israelow B; Iwasaki A; Azar MM;
J Infect Dis; 2022 Feb; 225(3):374-384. PubMed ID: 34718647
[TBL] [Abstract][Full Text] [Related]
14. SARS-CoV-2 Infection Severity Is Linked to Superior Humoral Immunity against the Spike.
Guthmiller JJ; Stovicek O; Wang J; Changrob S; Li L; Halfmann P; Zheng NY; Utset H; Stamper CT; Dugan HL; Miller WD; Huang M; Dai YN; Nelson CA; Hall PD; Jansen M; Shanmugarajah K; Donington JS; Krammer F; Fremont DH; Joachimiak A; Kawaoka Y; Tesic V; Madariaga ML; Wilson PC
mBio; 2021 Jan; 12(1):. PubMed ID: 33468695
[TBL] [Abstract][Full Text] [Related]
15. B careful: Humoral responses and COVID-19 severity.
Fanous H; Guerrero-Pena A; Pillai A
Sci Immunol; 2020 Dec; 5(54):. PubMed ID: 33277373
[TBL] [Abstract][Full Text] [Related]
16. Immune response variables and viral mutations impact on COVID-19 reinfection and relapse.
Sanaie S; Golipour E; Shamekh A; Sadaie MR; Mahmoodpoor A; Yousefi M
Int Immunopharmacol; 2021 Nov; 100():108108. PubMed ID: 34521025
[TBL] [Abstract][Full Text] [Related]
17. Prospects for durable immune control of SARS-CoV-2 and prevention of reinfection.
Cromer D; Juno JA; Khoury D; Reynaldi A; Wheatley AK; Kent SJ; Davenport MP
Nat Rev Immunol; 2021 Jun; 21(6):395-404. PubMed ID: 33927374
[TBL] [Abstract][Full Text] [Related]
18. Correlation of humoral immune responses to different SARS-CoV-2 antigens with virus neutralizing antibodies and symptomatic severity in a German COVID-19 cohort.
Rockstroh A; Wolf J; Fertey J; Kalbitz S; Schroth S; Lübbert C; Ulbert S; Borte S
Emerg Microbes Infect; 2021 Dec; 10(1):774-781. PubMed ID: 33830901
[TBL] [Abstract][Full Text] [Related]
19. Serosurvey in BNT162b2 vaccine-elicited neutralizing antibodies against authentic B.1, B.1.1.7, B.1.351, B.1.525 and P.1 SARS-CoV-2 variants.
Zani A; Caccuri F; Messali S; Bonfanti C; Caruso A
Emerg Microbes Infect; 2021 Dec; 10(1):1241-1243. PubMed ID: 34092181
[TBL] [Abstract][Full Text] [Related]
20. Persisting Neutralizing Activity to SARS-CoV-2 over Months in Sera of COVID-19 Patients.
Flehmig B; Schindler M; Ruetalo N; Businger R; Bayer M; Haage A; Kirchner T; Klingel K; Normann A; Pridzun L; Tougianidou D; Ranke MB
Viruses; 2020 Nov; 12(12):. PubMed ID: 33260809
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
